NASDAQ:QTRX - Quanterix Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Quanterix Corp Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $28.40 -0.32 (-1.11 %) (As of 02/20/2020 04:00 PM ET) Add Compare Today's Range$27.59Now: $28.40▼$28.7150-Day Range$21.63MA: $25.67▼$28.7252-Week Range$19.08Now: $28.40▼$36.15Volume60,373 shsAverage Volume127,047 shsMarket Capitalization$795.63 millionP/E RatioN/ADividend YieldN/ABeta1.27 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Quanterix Corporation, a life sciences company, develops and markets ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Simoa HD-1 instrument, a sensitive automated multiplex protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection technology in various applications, including direct detection of nucleic acids. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Analytical instruments Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:QTRX Previous Symbol CUSIPN/A CIK1503274 Webhttp://www.quanterix.com/ Phone617-301-9400Debt Debt-to-Equity Ratio0.06 Current Ratio7.61 Quick Ratio7.00Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$37.63 million Price / Sales21.14 Cash FlowN/A Price / Cash FlowN/A Book Value$1.85 per share Price / Book15.35Profitability EPS (Most Recent Fiscal Year)($1.43) Net Income$-31,540,000.00 Net Margins-75.78% Return on Equity-54.74% Return on Assets-37.51%Miscellaneous Employees177 Outstanding Shares28,015,000Market Cap$795.63 million Next Earnings Date3/16/2020 (Estimated) OptionableNot Optionable Receive QTRX News and Ratings via Email Sign-up to receive the latest news and ratings for QTRX and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:QTRX Rates by TradingView Quanterix (NASDAQ:QTRX) Frequently Asked Questions What is Quanterix's stock symbol? Quanterix trades on the NASDAQ under the ticker symbol "QTRX." When is Quanterix's next earnings date? Quanterix is scheduled to release their next quarterly earnings announcement on Monday, March 16th 2020. View Earnings Estimates for Quanterix. What price target have analysts set for QTRX? 2 equities research analysts have issued 1 year target prices for Quanterix's shares. Their forecasts range from $35.00 to $35.00. On average, they anticipate Quanterix's share price to reach $35.00 in the next year. This suggests a possible upside of 23.2% from the stock's current price. View Analyst Price Targets for Quanterix. What is the consensus analysts' recommendation for Quanterix? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Quanterix in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Quanterix. What are Wall Street analysts saying about Quanterix stock? Here are some recent quotes from research analysts about Quanterix stock: 1. According to Zacks Investment Research, "Quanterix Corporation is a developer of tools in high definition diagnostics. The Company focuses on research and diagnostics for brain injuries, heart disease, cancer and other diseases with its technology. It offers Simoa consumables, which include Simoa Discs, Simoa Cuvettes, Simoa Sealing Oil, Simoa Buffers and Disposable Tips. The company services include Simoa Accelerator Lab and custom assay development services. Quanterix Corporation is based in LEXINGTON, United States. " (1/8/2020) 2. Canaccord Genuity analysts commented, "We come away feeling good about the momentum building, as QTRX is ~3% penetrated into the life sciences research market. QTRX is executing well above its 40%+ rev. growth target, and sits on new product launches. We reiterate our BUY, raise our PT to $38 from $35. One competitor just shut its doors. We were recently surprised to hear directly from privately-held Singulex CEO Guido Baechler (who employed 71 people and invested $225M+ into its business) that the company shuttered its business on June 28, 2019. With one less competitor, we expect QTRX to continue steamrolling ahead. QTRX is well positioned for elite growth. QTRX has grown its top line +70% in its trailing four quarters and is now rolling out new products, and feels good about Street’s $50.7M (+35%) estimate for 2019." (7/24/2019) Has Quanterix been receiving favorable news coverage? News articles about QTRX stock have trended positive recently, according to InfoTrie Sentiment Analysis. The research firm identifies positive and negative news coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Quanterix earned a news impact score of 2.3 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View News Stories for Quanterix. Who are some of Quanterix's key competitors? Some companies that are related to Quanterix include Horiba (HRIBF), Accelerate Diagnostics (AXDX), Pacific Biosciences of California (PACB), Fluidigm (FLDM), Eyepoint Pharmaceuticals (EYPT), Harvard Bioscience (HBIO), HTG Molecular Diagnostics (HTGM), BioNano Genomics (BNGO), Aethlon Medical (AEMD), Arrayit (ARYC), Scientific Industries (SCND), Precipio (PRPO), Pressure Biosciences (PBIO) and PositiveID (PSID). What other stocks do shareholders of Quanterix own? Based on aggregate information from My MarketBeat watchlists, some companies that other Quanterix investors own include Allena Pharmaceuticals (ALNA), Crispr Therapeutics (CRSP), Spero Therapeutics (SPRO), Veracyte (VCYT), KeyCorp (KEY), Akoustis Technologies (AKTS), Ardelyx (ARDX), Cara Therapeutics (CARA), Editas Medicine (EDIT) and Huntington Bancshares (HBAN). Who are Quanterix's key executives? Quanterix's management team includes the folowing people: Mr. E. Kevin Hrusovsky, Chairman, Pres & CEO (Age 58)Dr. David R. Walt, Co-Founder, Chairman of Scientific Advisory Board & Director (Age 66)Dr. David C. Duffy Ph.D., Sr. VP of R&D and CTO (Age 48)Mr. Amol Chaubal, Chief Financial Officer (Age 43)Mr. Bruce J. Bal, VP of Operations, Service & Quality (Age 60) When did Quanterix IPO? (QTRX) raised $50 million in an IPO on Thursday, December 7th 2017. The company issued 3,300,000 shares at $14.00-$16.00 per share. J.P. Morga and Leerink Partners acted as the underwriters for the IPO and BTIG and Evercore ISI were co-managers. Who are Quanterix's major shareholders? Quanterix's stock is owned by many different of institutional and retail investors. Top institutional shareholders include FMR LLC (3.17%), Royce & Associates LP (1.86%), State Street Corp (0.86%), Bank of New York Mellon Corp (0.74%), Kornitzer Capital Management Inc. KS (0.73%) and Geode Capital Management LLC (0.68%). Company insiders that own Quanterix stock include David C Duffy, Dawn Mattoon, E Kevin Hrusovsky, Ernest Orticerio, John M Connolly, Joseph Driscoll, Marijn E Dekkers, Mark T Roskey and Martin D Madaus. View Institutional Ownership Trends for Quanterix. Which major investors are selling Quanterix stock? QTRX stock was sold by a variety of institutional investors in the last quarter, including Essex Investment Management Co. LLC, Barclays PLC, Credit Suisse AG, Bank of America Corp DE, Advisory Research Inc., AQR Capital Management LLC, Carnegie Capital Asset Management LLC and Geode Capital Management LLC. Company insiders that have sold Quanterix company stock in the last year include David C Duffy, Dawn Mattoon, E Kevin Hrusovsky, Marijn E Dekkers, Mark T Roskey and Martin D Madaus. View Insider Buying and Selling for Quanterix. Which major investors are buying Quanterix stock? QTRX stock was bought by a variety of institutional investors in the last quarter, including FMR LLC, Kornitzer Capital Management Inc. KS, Bank of Montreal Can, State Street Corp, Platinum Investment Management Ltd., Renaissance Technologies LLC, Goldman Sachs Group Inc. and First Republic Investment Management Inc.. View Insider Buying and Selling for Quanterix. How do I buy shares of Quanterix? Shares of QTRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is Quanterix's stock price today? One share of QTRX stock can currently be purchased for approximately $28.40. How big of a company is Quanterix? Quanterix has a market capitalization of $795.63 million and generates $37.63 million in revenue each year. The company earns $-31,540,000.00 in net income (profit) each year or ($1.43) on an earnings per share basis. Quanterix employs 177 workers across the globe.View Additional Information About Quanterix. What is Quanterix's official website? The official website for Quanterix is http://www.quanterix.com/. How can I contact Quanterix? Quanterix's mailing address is 900 MIDDLESEX TURNPIKE, BILLERICA MA, 01821. The company can be reached via phone at 617-301-9400. MarketBeat Community Rating for Quanterix (NASDAQ QTRX)Community Ranking: 2.3 out of 5 ( )Outperform Votes: 224 (Vote Outperform)Underperform Votes: 267 (Vote Underperform)Total Votes: 491MarketBeat's community ratings are surveys of what our community members think about Quanterix and other stocks. Vote "Outperform" if you believe QTRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe QTRX will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/20/2020 by MarketBeat.com StaffFeatured Article: Do You Need a Fiduciary?
